We observed a significantly weaker expression of ACCN1 in neuroblastomas with MYCN amplification (p<0.01) [34] or with 1p36 loss of heterozygosity (p<0.01) [34] compared to tumors without these alterations. The gene discussed is ASIC2; the disease is neuroblastoma.